UTHealth Houston is the first institution in Houston to administer an FDA-approved drug, Kisunla (donanemab-azbt), for the ...

Eli Lilly LLY announced that its Alzheimer's disease (AD) drug Kisunla (donanemab) has been approved for use in Japan. The ...

The two FDA-approved drugs have demonstrated in clinical trials the capability to slow cognitive decline by several months, The Washington Post reported Oct. 8.

A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

The U.S. Food and Drug Administration (FDA) has taken a move in the management of Alzheimer’s disease by approving a drug known as Kisunla (donanemab-azbt). Kisunla focuses on patients diagnosed with ...

Eli Lilly on Tuesday said Japan's Ministry of Health, Labour and Welfare Japan approved Kisunla for adults with early symptomatic Alzheimer's, including those with mild cognitive impairment as well as ...

INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli ...

(RTTNews) - Eli Lilly and Company (LLY) Tuesday said its Kisunla for the treatment of adults with early symptomatic Alzheimer's disease has been approved by the Ministry of Health, Labour and Welfare ...

The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks ...